GU Cancers 2025 | CTC RNA biomarker for bavdegalutamide in mCRPC without AR mutations

Xin Gao • 13 Feb 2025

GU Cancers 2025

Xin Gao, MD, Massachusetts General Hospital Cancer Center, Boston, MA, comments on an analysis of a circulating tumor cell (CTC) RNA biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with bavdegalutamide in a Phase I/II study. Findings suggest that a lower pre-treatment CTC biomarker score was associated with stable disease and longer time on therapy, despite the absence of AR T878/H875 mutations. These results highlight the potential for biomarker-driven patient selection for bavdegalutamide and other androgen receptor-targeting PROTACs. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.